New shot shows promise for stubborn eczema

NCT ID NCT05923099

Completed Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

Summary

This completed study tested four different doses of an experimental drug called LEO 138559 (temtokibart) against a placebo in 262 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to find the most effective and safest dose to reduce the severity and extent of the skin condition. Participants received injections under the skin for 16 weeks and were followed for another 16 weeks to monitor their skin and any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

LEO Investigational Site

Fountain Valley, California, 92708, United States
LEO Investigational Site

Los Angeles, California, 90045, United States
LEO Investigational Site

San Francisco, California, 94115, United States
LEO Investigational Site

Hialeah, Florida, 33012, United States
LEO Investigational Site

Ann Arbor, Michigan, 48103, United States
LEO Investigational Site

New York, New York, 10029, United States
LEO Investigational Site

Raleigh, North Carolina, 27609, United States
LEO Investigational Site

Cincinnati, Ohio, 45219, United States
LEO Investigational Site

Mayfield Heights, Ohio, 44124, United States
LEO Investigational Site

North Charleston, South Carolina, 29420, United States
LEO Investigational Site

Edmonton, Albana, T5J 3S9, Canada
LEO Investigational Site

Calgary, Alberta, T2J 7E1, Canada
LEO Investigational Site

Calgary, Alberta, T2W 4X9, Canada
LEO Investigational Site

Edmonton, Alberta, T6G 1C3, Canada
LEO Investigational Site

Surrey, British Columbia, V3R 6A7, Canada
LEO Investigational Site

Mississauga, Ontario, L4Y 4C5, Canada
LEO Investigational Site

Sherbrooke, Quebec, J1G 1X9, Canada
LEO Investigational Site

Verdun, Quebec, H4G 3E7, Canada
LEO Investigational Site

Náchod, 547 01, Czechia
LEO Investigational Site

Prague, 100 34, Czechia
LEO Investigational Site

Prague, 150 00, Czechia
LEO Investigational Site

Martigues, Bouches-du-Rhône, 13500, France
LEO Investigational Site

Dijon, 21000, France
LEO Investigational Site

Nice, 06000, France
LEO Investigational Site

Paris, 75010, France
LEO Investigational Site

Rouen, 76031, France
LEO Investigational Site

Augsburg, 86179, Germany
LEO Investigational Site

Bad Bentheim, 48455, Germany
LEO Investigational Site

Berlin, 10117, Germany
LEO Investigational Site

Dresden, 01307, Germany
LEO Investigational Site

Frankfurt am Main, 60590, Germany
LEO Investigational Site

Freiburg im Breisgau, 79104, Germany
LEO Investigational Site

Gera, 07548, Germany
LEO Investigational Site

Kiel, 24105, Germany
LEO Investigational Site

Leipzig, 04103, Germany
LEO Investigational Site

Mahlow, 15831, Germany
LEO Investigational Site

Münster, 48149, Germany
LEO Investigational Site

Debrecen, 4032, Hungary
LEO Investigational Site

Pécs, 7632, Hungary
LEO Investigational Site

Szeged, 6720, Hungary
LEO Investigational Site

Fukuoka, Fukuoka, 815-8588, Japan
LEO Investigational Site

Kobe, Hyōgo, 657-0846, Japan
LEO Investigational Site

Yokohama, Kanagawa, 220-6208, Japan
LEO Investigational Site

Yokohama, Kanagawa, 231-0801, Japan
LEO Investigational Site

Takatsuki-shi, Osaka, 569-0824, Japan
LEO Investigational Site

Koto-ku, Tokyo, 136-0074, Japan
LEO Investigational Site

Takaoka-shi, Toyama, 933-0871, Japan
LEO Investigational Site

Tokyo, 167-0051, Japan
LEO Investigational Site

Wroclaw, Lower Silesian Voivodeship, 50-450, Poland
LEO Investigational Site

Krakow, 30-033, Poland
LEO Investigational Site

Krakow, 31-011, Poland
LEO Investigational Site

Malbork, 82-200, Poland
LEO Investigational Site

Mikołów, 43-190, Poland
LEO Investigational Site

Wroclaw, 50-224, Poland
LEO Investigational Site

Cluj-Napoca, 400152, Romania
LEO Investigational Site

Iași, 700291, Romania
LEO Investigational Site

Timișoara, 300757, Romania
LEO Investigational Site

Badalona, Barcelona, 08915, Spain
LEO Investigational Site

Alcobendas, 5-28100, Spain
LEO Investigational Site

Alicante, 03010, Spain
LEO Investigational Site

Barcelona, 08907, Spain
LEO Investigational Site

Córdoba, 14004, Spain
LEO Investigational Site

Madrid, 28046, Spain
LEO Investigational Site

Zaragoza, 50009, Spain
LEO Investigational Site

Edinburgh, EH16 4SA, United Kingdom
LEO Investigational Site

Harrow, HA1 3UJ, United Kingdom
LEO Investigational Site

London, E1 1FR, United Kingdom
LEO Investigational Site

Manchester, M23 9QZ, United Kingdom
LEO Investigational Site

Southampton, SO16 6YD, United Kingdom
LEO Investigational Site

Walsall, WS2 9PS, United Kingdom
LEO Investigatonal Site

Ostrava-Poruba, 708 52, Czechia
LEO investigational Site

New Albany, Indiana, 47150, United States
LEO investigational site

Indianapolis, Indiana, 46250, United States

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS